Using a data sample from the CDC National Program for Cancer Registries, investigators determined how demographic factors — age, race, and sex — impact 5-year survival rates for HPV-associated cancers from initial diagnosis until death.
HIV infection may not have a contributory effect on the incidence of invasive cervical cancer (ICC) in women as they age.
Small study also showed that pembrolizumab does not significant impair radiation or chemotherapy dosing.
A literature review noted improvements in quality of life after patients were coached and educated following radiotherapy for HPV-associated oropharyngeal cancers.
Protein produced by chronically infected cells in persons with HPV16 infection serves as a biomarker for risk of cancer of the oropharynx.
Self-persuasion is more effective than external persuasion for motivating low-income parents to vaccinate their children against HPV.
Fewer cervical cell anomalies were present on cervical cancer screens of young women in Canada who received the HPV vaccine through a school-based program.
Although HPV vaccination is expected to decrease the cancer burden from HPV across all racial and ethnic groups, some disparities are expected to persist and widen if their causes are not addressed, including lack of access to screening, timely diagnoses, and treatment.
An analysis has recommended expanding HPV vaccination programs to include males in Canada because it will help protect them against HPV-related cancers.
Oropharyngeal cancer patients with detectable traces of human papillomavirus type 16 (HPV16) in their saliva after cancer treatment are at an increased risk for recurrence.
The presence of certain human papillomavirus (HPV)-16 antibodies in the blood is associated with improved survival rates for patients with HPV-related oropharyngeal carcinoma.
A prospective study found that patients with human papillomavirus-related disease had better treatment response than HPV-negative patients.
A drug typically used to treat infection of the retina in people with AIDS has been shown, for the first time, to sensitize cervical cancer to both chemotherapy and radiotherapy.
An international team of researchers identified two biomarkers that were good at predicting a patient's resistance to radiation therapy for squamous cell cancer of the head and neck.
The quality of cancer stem cells, rather than their quantity, may be the factor that leads to better survival in certain patients with oral cancer.
Researchers from Boston, Massachusetts; Mexico; and Norway have completed a comprehensive genomic analysis of cervical cancer in two patient populations.
The human papillomavirus (HPV) may be to blame for the alarming increase of young adults with oropharyngeal cancer.
A new understanding of the genetic process that can lead to cervical cancer may help improve diagnosis of potentially dangerous lesions for some women.
Antibodies against the human papillomavirus (HPV) may help identify those with a greatly increased risk for HPV-related cancer of the oropharynx.
Sign Up for Free e-newsletters
- Incidence of Post-traumatic Stress Disorder High Among Patients With Cancer
- Long-Term Night Shift Work Associated With Cancer Risk in Women
- Distress, Neuroticism Predict Long-term Emotional Distress After Cancer Diagnosis
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- FDA Grants Breakthrough Therapy Designation to Lenvatinib Plus Pembrolizumab for RCC
- Bacteria in Probiotics Carry Potential Risks for Immunocompromised Patients
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Breast Cancer Deaths Decrease Sharply Since 2000
- Identifying the Psychosocial Needs of Young Adults With Metastatic Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|